Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Search
Global Top Employer 2023
Global Top Employer 2023
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
preventive care cat veterinarian
What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!
Animal Health Collaboration with Novozymes
Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Sabine Reinig
For Sabine, who leads Boehringer Ingelheim's global people strategy, continuous development is the essence of a successful career. Read for more details!
COVID-19: Ivermectin in Animal Health products
Boehringer Ingelheim manufactures several veterinary products containing ivermectin. They are not approved or suitable for use in humans to try to prevent or treat COVID-19.
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Partnering with Boehringer Ingelheim: BIO International 2024
Learn about innovation and partnering with Boehringer Ingelheim human pharma, animal health and biopharma contract manufacturing at BIO International 2024